2448 completed, 543 unknown, 392 terminated, 344 recruiting. 4131 Phase 3, 610 Phase 2.
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS) | Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 120 | 2027-10-01 | 2026-10-30 |
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy MSC, marrow, Placebo - Perinatal Arterial Ischemic Stroke, Perinatal Asphyxia | Phase 2 / Phase 3 | Not yet recruiting | UMC Utrecht | 162 | 2027-04-01 | 2026-09-21 |
| Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 1266 | 2027-04-01 | 2026-11-03 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) treprostinil SMI (treprostinil inhalation spray) - Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Not yet recruiting | United Therapeutics | 400 | 2027-03-01 | 2026-11-06 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension N0877, Benicar HCT ® Tablets 40 mg/25 mg - Essential Arterial Hypertension | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2027-01-30 | 2026-10-26 | |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant Intravenous tenecteplase (TNK), Placebo - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Hackensack Meridian Health | 660 | 2027-01-01 | 2026-06-02 |
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| CiLostAzol for pReventIon of Recurrent sTroke in Africa Cilostazol 100 mg - Stroke | Phase 3 | Not yet recruiting | Northern California Institute of Research and Education | 1100 | 2027-01-01 | 2026-11-12 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 300 | 2026-12-30 | 2026-11-12 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke Tirofiban Injection - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Xinqiao Hospital of Chongqing | 1192 | 2026-12-19 | 2026-11-06 |
| INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre - Stroke, Acute Ischemic, Medium Vessel Occlusion | Phase 3 | Not yet recruiting | University of Calgary | 800 | 2026-12-15 | 2026-10-30 |
| A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | Janssen Research & Development, LLC | 1000 | 2026-12-14 | 2026-11-04 |
| Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome Vitamin K Antagonist - Drug, Anticoagulant Therapy Discontinuation - Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 234 | 2026-12-01 | 2026-10-15 |
Showing 20 of 4131. Sign in to see all of them.
Hypertension (635) · Stroke (411) · Multiple Myeloma (384) · Ischemic Stroke (328) · Coronary Artery Disease (319) · Myocardial Infarction (216) · Cardiovascular Diseases (214) · Coronary Disease (154) · Atherosclerosis (149) · Heart Diseases (137) · Myocardial Ischemia (135) · Venous Thromboembolism (132) · Hypertension, Pulmonary (130) · Acute Coronary Syndrome (127) · Essential Hypertension (124)
Cardiovascular Diseases (3917) · Pathological Conditions, Signs and Symptoms (1243) · Nervous System Diseases (1007) · Pathologic Processes (938) · Central Nervous System Diseases (933) · Brain Diseases (923) · Heart Diseases (897) · Cerebrovascular Disorders (864) · Myocardial Ischemia (740) · Arterial Occlusive Diseases (600) · Immune System Diseases (577) · Arteriosclerosis (567) · Hemic and Lymphatic Diseases (528) · Hematologic Diseases (481)
Dexamethasone (205) · Aspirin (134) · Clopidogrel (126) · Amlodipine (114) · Bortezomib (106) · Lenalidomide (100) · Rivaroxaban (91) · Hydrochlorothiazide (79) · Enoxaparin (72) · Valsartan (69) · Ticagrelor (63) · daratumumab (61) · Atorvastatin (58) · Cyclophosphamide (58) · Tenecteplase (56)
Novartis (85) · Boehringer Ingelheim (72) · Novartis Pharmaceuticals (70) · National Heart, Lung, and Blood Institute (NHLBI) (69) · Assistance Publique - Hôpitaux de Paris (67) · AstraZeneca (49) · Sanofi (49) · Bayer (48) · GlaxoSmithKline (41) · Takeda (41) · Beijing Tiantan Hospital (39) · Boston Scientific Corporation (32) · Janssen Research & Development, LLC (31) · Organon and Co (29) · Pfizer (27)
United States (1370) · Germany (688) · Canada (676) · France (622) · China (530) · Italy (529) · United Kingdom (510) · Spain (507) · Poland (412) · Netherlands (400) · Australia (384) · South Korea (377) · Belgium (365) · Czechia (324) · Brazil (315)
PMID 31867054, PMID 35224730, PMID 36326435, PMID 18190818, PMID 2375765, PMID 33337539, PMID 36700520, PMID 42573020, PMID 33089502, PMID 35244208, PMID 22689675, PMID 24081972, PMID 27160944, PMID 34022170, PMID 34487721, PMID 34515113, PMID 35570249, PMID 37565307, PMID 37870112, PMID 38682786, PMID 40163217, PMID 16731270, PMID 18783301, PMID 19463432, PMID 20129555, PMID 20818886, PMID 21899409, PMID 22017936, PMID 22115661, PMID 23232250, PMID 23312695, PMID 24746650, PMID 26089177, PMID 27162632, PMID 29910052, PMID 31221778, PMID 32609313, PMID 33502773, PMID 34289038, PMID 34932836, PMID 35916348, PMID 37591523, PMID 41114449, PMID 42035974, PMID 12807523, PMID 17296825, PMID 17825712, PMID 18806012, PMID 20136164, PMID 20175775
2023 (50), 2025 (38), 2018 (31), 2017 (30), 2009 (27), 2014 (25), 2008 (24), 2016 (23), 2015 (22), 2019 (22), 2005 (20), 2004 (7), M01RR000070 (5), M01RR000750 (5), M01RR006022 (5)